Literature DB >> 6340634

Dexamethasone suppression tests in antidepressant treatment of melancholia. The process of normalization and test-retest reproducibility.

J F Greden, R Gardner, D King, L Grunhaus, B J Carroll, Z Kronfol.   

Abstract

Pilot studies suggest that changes in response to the dexamethasone suppression test (DST) in melancholic patients receiving antidepressants might represent a laboratory marker of clinical progress. We performed weekly DSTs in 31 hospitalized patients with major depressive disorder, primary and endogenous subtypes, during drug-free and subsequent treatment periods. Most nonsuppressors had progressive normalization of DST responses in conjunction with clinical improvement, DST normalization usually preceded or coincided with good clinical response, and failure to normalize was often associated with poorer clinical outcome. Occasional patients with baseline dexamethasone suppression become nonsuppressive after withdrawal from medication, but the DST has no apparent value as a serial marker in patients with well-documented normal DST findings. Our results extend the construct validity of the DST as a state-related marker in nonsuppressors and suggest future clinical applications.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6340634     DOI: 10.1001/archpsyc.1983.01790050019002

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  29 in total

1.  Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.

Authors:  Matthew N Hill; Erica J Carrier; Ryan J McLaughlin; Anna C Morrish; Sarah E Meier; Cecilia J Hillard; Boris B Gorzalka
Journal:  J Neurochem       Date:  2008-07-15       Impact factor: 5.372

Review 2.  Reliability of hypothalamic-pituitary-adrenal axis assessment methods for use in population-based studies.

Authors:  Sherita Hill Golden; Gary S Wand; Saurabh Malhotra; Ihab Kamel; Karen Horton
Journal:  Eur J Epidemiol       Date:  2011-04-30       Impact factor: 8.082

3.  Management of depression in general practice.

Authors:  S Brandon
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-01

4.  Regulation of corticosteroid receptor gene expression in depression and antidepressant action.

Authors:  N Barden
Journal:  J Psychiatry Neurosci       Date:  1999-01       Impact factor: 6.186

5.  Prenatal immune challenge alters the hypothalamic-pituitary-adrenocortical axis in adult rats.

Authors:  J M Reul; I Stec; G J Wiegers; M S Labeur; A C Linthorst; E Arzt; F Holsboer
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

Review 6.  Blood-based biomarkers predicting response to antidepressants.

Authors:  Yasmin Busch; Andreas Menke
Journal:  J Neural Transm (Vienna)       Date:  2018-01-27       Impact factor: 3.575

Review 7.  Corticosteroid-serotonin interactions in depression: a review of the human evidence.

Authors:  Richard J Porter; Peter Gallagher; Stuart Watson; Allan H Young
Journal:  Psychopharmacology (Berl)       Date:  2004-03-09       Impact factor: 4.530

8.  Prediction of therapeutic response in acute treatment with antidepressants. Results of an empirical study involving 159 endogenous depressive inpatients.

Authors:  H J Möller; G Fischer; D von Zerssen
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1987

9.  The dexamethasone suppression test in depressive and schizophrenic patients under controlled treatment conditions.

Authors:  H J Möller; W Kissling; P Bottermann
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1986

10.  The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression.

Authors:  Cornelius Schüle; Thomas C Baghai; Daniela Eser; Sibylle Häfner; Christoph Born; Sascha Herrmann; Rainer Rupprecht
Journal:  PLoS One       Date:  2009-01-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.